Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis: The loire valley atrial fibrillation project

Thrombosis and Haemostasis

Volumn 115, Issue 5, 2016, Pages 1056-1063

  Philippart, Raphael ^a   Brunet Bernard, Anne ^a   Clementy, Nicolas ^a   Bourguignon, Thierry ^a   Mirza, Alain ^a   Angoulvant, Denis ^a   Babuty, Dominique ^a   Lip, Gregory Y H ^b   Fauchier, Laurent ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; Biological valve prosthesis; Ischaemic stroke

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHADS2 SCORE; COMPARATIVE STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VALVE BIOPROSTHESIS; HEART VALVE REPLACEMENT; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; ADVERSE DEVICE EFFECT; ANTAGONISTS AND INHIBITORS; BIOPROSTHESIS; CEREBROVASCULAR ACCIDENT; COMPLICATION; FRANCE; HEART VALVE PROSTHESIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK FACTOR; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOPROSTHESIS; FEMALE; FRANCE; HEART VALVE PROSTHESIS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOEMBOLISM; VITAMIN K;

EID: 84964827958     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-01-0007     Document Type: Article

References (28)

1. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
2. Authors/Task Force Members, Camm AJ, Lip GYH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-76.
4. Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 593S-629S.
5. Meschengieser SS, Fondevila CG, Frontroth J, et al. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997; 113: 910-916.
6. McClung JA, Stein JH, Ambrose JA, et al. Prosthetic heart valves: a review. Prog Cardiovasc Dis 1983; 26: 237-270.
7. David TE, Pollick C, Bos J. Aortic valve replacement with stentless porcine aortic bioprosthesis. J Thorac Cardiovasc Surg 1990; 99: 113-118.
8. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 457S-482S.
9. Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 2008; 34: 73-92.
10. Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 2005; 129: 1024-1031.
11. Nowell J, Wilton E, Markus H, et al. Antithrombotic therapy following bioprosthetic aortic valve replacement. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 2007; 31: 578-585.
12. Philippart R, Brunet-Bernard A, Bourguignon T, et al. CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis. J Am Coll Cardiol 2016; Epub ahead of print.
13. Philippart R, Brunet-Bernard A, Clementy N, et al. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 2015; 36: 1822-1830.
14. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25: 1111-1119.
15. Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. J Am Med Assoc 2012; 308: 2118-2125.
16. Jamieson WRE, Moffatt-Bruce SD, Skarsgard P, et al. Early antithrombotic therapy for aortic valve bioprostheses: is there an indication for routine use? Ann Thorac Surg 2007; 83: 549-557.
17. Aramendi JI, Mestres C-A, Mestres C-A, et al. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 2005; 27: 854-860.
18. Brueck M, Kramer W, Vogt P, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 2007; 32: 108-112.
19. Whitley WS, Glas KE. An argument for routine ultrasound screening of the thoracic aorta in the cardiac surgery population. Semin Cardiothorac Vasc Anesth 2008; 12: 290-297.
20. Baglin TP, Keeling DM, Watson HG, et al. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006; 132: 277-285.
21. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52: e1-142.
22. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-2496.
23. Colli A, Verhoye J-P, Heijmen R, et al. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 2008; 33: 531-536.
24. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med 2013; 369: 1206-1214.
25. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
26. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013; 369: 2093-2104.
27. De Caterina R, Camm AJ. What is 'valvular' atrial fibrillation? A reappraisal. Eur Heart J 2014; 35: 3328-3335.
28. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.